Study guide
6.2 Tc-99m Bone, Renal, and GU Agents
Certified Nuclear Medicine Technologist CNMT
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current CNMT Exam Facts 1.2 How to Use This Guide
2 Radiation Physics Fundamentals
2.1 Radioactive Materials, Isotopes, and Decay Modes 2.2 Decay Calculations and Counting Statistics 2.3 Interactions of Radiation with Matter 2.4 Radiation Detector Types and Principles
3 Biological Effects & ALARA
3.1 Biological Effects of Radiation Exposure 3.2 ALARA and Protection Calculations 3.3 Dose Limits, Surveys, and Personal Monitoring
4 NRC & Regulatory Compliance
4.1 NRC Areas, Spills, Waste, and Records 4.2 Written Directives and DOT Shipping 4.3 EPA, OSHA, HIPAA, FDA, and USP Standards 4.4 Radioactive Waste Disposal and Regulatory Records
5 Generators & Kit Preparation
5.1 Radionuclide Generators and Quality Control 5.2 Radiopharmaceutical Kit Preparation 5.3 Radiopharmaceutical Quality Control
6 Tc-99m Diagnostic Agents
6.1 Tc-99m Cardiac Imaging Agents 6.2 Tc-99m Bone, Renal, and GU Agents 6.3 Tc-99m GI and Hepatobiliary Agents 6.4 Tc-99m CNS, Infection, and Labeled Cells
7 Non-Tc Diagnostic & PET Agents
7.1 Iodine and Indium Diagnostic Agents 7.2 Gallium, Thallium, Xenon, and Miscellaneous Agents 7.3 PET Radiopharmaceuticals 7.4 Neurologic, Breast, and Neuroendocrine PET Agents
8 Therapeutics, Adjuncts & Administration
8.1 Therapeutic Radiopharmaceuticals 8.2 Interventional and Adjunct Pharmaceuticals 8.3 Blood Labeling and Administration Techniques 8.4 Blockade, Comfort, and Gastrointestinal Adjunct Agents
9 Non-Imaging Instrumentation
9.1 Well Counters, Probes, and Survey Meters 9.2 Dose Calibrator Quality Control 9.3 Auxiliary and Patient Care Equipment
10 Imaging Systems & Quality Control
10.1 Gamma Camera Quality Control 10.2 SPECT and SPECT/CT Systems 10.3 PET and PET/CT Systems and QC 10.4 CT Systems, PACS, and Information Systems 10.5 CT Radiation Dose, Safety Alerts, and Protocol Optimization
11 Pulmonary, Bone, Oncology & Infection Imaging
11.1 Pulmonary Imaging Procedures 11.2 Bone and Musculoskeletal Imaging 11.3 Oncology Imaging Procedures 11.4 Infection Imaging Procedures
12 Renal, Endocrine & Hematopoietic Imaging
12.1 Renal and Genitourinary Imaging 12.2 Endocrine Imaging (Thyroid, Parathyroid, Adrenal) 12.3 Hematopoietic and Bone Marrow Imaging 12.4 Thyroid Uptake Measurement and Radioiodine Survey Technique
13 Cardiovascular Procedures
13.1 Myocardial Perfusion Imaging 13.2 Cardiac Function, Viability, and Special Studies 13.3 Exercise and Pharmacologic Stress Testing
14 GI, CNS, Therapy & Hybrid CT Procedures
14.1 Gastrointestinal Procedures 14.2 Central Nervous System Procedures 14.3 Radionuclide Therapy Procedures 14.4 CT and Hybrid Imaging in Nuclear Medicine 14.5 CSF Studies: Cisternography, Leak Localization, and Shunt Patency
15 Patient Care & Clinical Workflow
15.1 Patient Care, Education, and Consent 15.2 Scheduling and Radiopharmaceutical Procurement 15.3 Acquisition, Positioning, and Image Quality 15.4 Image Processing and Quantitative Analysis 15.5 Non-Imaging Studies: Specimens, Counting, and Error Analysis
6.2 Tc-99m Bone, Renal, and GU Agents
Key Takeaways Explain This Topic AI
Tc-99m MDP and HDP bind bone by chemiadsorption to hydroxyapatite; uptake reflects osteoblastic activity and blood flow
Typical adult bone dose is about 20–30 mCi IV with delayed whole-body imaging at 2–4 hours; hydrate and void to clear soft tissue and bladder
Tc-99m DTPA measures GFR (filtered); MAG3 is secreted by proximal tubules (effective renal plasma flow–type agent); DMSA binds renal cortex for scarring/morphology
Extraosseous soft-tissue uptake on bone scan has a differential: renal failure, free Tc, infiltrates, calcifications, tumor, technical errors
Patient prep for renograms includes hydration, voiding, and appropriate ACE-inhibitor or diuretic (furosemide) protocols when ordered
Last updated: August 2026
6.2 Tc-99m Bone, Renal, and GU Agents
Quick Answer: MDP/HDP → bone via chemiadsorption to hydroxyapatite (~20–30 mCi, image 2–4 h). DTPA → GFR filtration; MAG3 → tubular secretion ; DMSA → cortical binding for scars. Always link agent → physiology → indication, and know extraosseous bone-scan causes.
- Bone Scintigraphy: MDP and HDP
- Mechanism
Tc-99m medronate (MDP) and Tc-99m oxidronate (HDP) are diphosphonates. After IV injection they clear from blood, are filtered by the kidneys, and bind to bone mineral by chemiadsorption onto hydroxyapatite , especially in regions of high osteoblastic activity and blood flow. They do not primarily label osteoclasts or pure lytic non-reactive lesions—purely destructive lesions may be cold or subtle until a reactive rim forms.
- Agent Full name / note Mechanism Typical adult dose
- MDP Medronate Chemiadsorption to bone mineral ~20–30 mCi (740–1110 MBq) IV
- HDP Oxidronate Same class; often slightly higher bone-to-soft-tissue ~20–30 mCi IV
- Indications
- Metastatic survey (prostate, breast, lung, and other osteoblastic-prone cancers)
- Occult fracture, stress fracture, shin splints vs fracture patterns
- Osteomyelitis vs cellulitis (three-phase bone scan)
- Prosthesis loosening/infection workups (often with complementary studies)
- Paget disease, reflex sympathetic dystrophy patterns, metabolic bone disease surveys
- Protocol Essentials
Administration: IV. Delay: whole-body or spot delayed images typically 2–4 hours after injection (pediatric timing and doses weight-based). Three-phase study: flow (dynamic), blood pool (immediate), and delayed bone phase—for infection/trauma questions.
Prep: hydrate; void immediately before imaging to reduce bladder artifact over pelvis; remove metal; note recent surgery, trauma, or dental work. SPECT/SPECT-CT improves spine and complex anatomy specificity.
Extraosseous Soft-Tissue Uptake — High-Yield Differential
Exam favorites ask why soft tissue is hot on a “bone” scan:
- Finding / cause Mechanism / note
- Renal failure / poor clearance Prolonged soft-tissue and blood-pool activity
- Free Tc-99m pertechnetate Stomach, thyroid, salivary activity; kit QC or prep error
- Injection infiltrate Focal soft-tissue hot spot at injection site
- Urine contamination Clothing, skin—wash and re-image
- Soft-tissue calcification Myositis ossificans, calcific tendinitis, mucinous mets
- Amyloid, hypercalcemia patterns Soft-tissue microcalcification binding
- Pleural effusion / ascites Tracer in fluid collections
- Tumor (e.g., some breast, liver mets) Extraosseous diphosphonate uptake
- Breast / tumor implants artifacts Attenuation or uptake patterns
- Radiopharmaceutical impurity / colloid formation Liver/spleen visualization
Liver-spleen visualization on a bone kit often means colloid or hydrolyzed reduced Tc , not normal MDP biodistribution—flag radiopharmacy/QC issues.
Renal and GU Agents: Match Physiology to Tracer
Agent Localization mechanism Functional readout Typical adult dose (order of magnitude) Primary indications
Tc-99m DTPA Glomerular filtration GFR estimation; renogram ~5–10 mCi (185–370 MBq) GFR, obstruction (with diuretic), renal blood flow patterns
Tc-99m MAG3 (mertiatide) Tubular secretion (proximal tubule) Effective renal plasma flow–type curve; excellent extraction ~5–10 mCi Renography, obstruction, transplant, poor renal function (preferred over DTPA when function low)
Tc-99m DMSA (succimer) Cortical binding (proximal tubular cells) Morphology, relative function, scars ~1–5 mCi (often lower) Pyelonephritis scars, cortical defects, differential function
DTPA — Filtration
Tc-99m DTPA is filtered by glomeruli with negligible tubular secretion/reabsorption in standard teaching. Clearance approximates GFR when technique is good. Dynamic renogram curves show uptake and excretion. With furosemide (Lasix) challenge, washout distinguishes mechanical obstruction from dilated non-obstructed systems. With ACE-inhibitor (captopril) renography (protocol-specific), look for functionally significant renovascular hypertension patterns.
Limitation: low GFR → poor extraction and noisy curves; many labs prefer MAG3 in compromised kidneys.
MAG3 — Tubular Secretion
Tc-99m mertiatide (MAG3) is extracted mainly by proximal tubular secretion , so first-pass extraction is higher than DTPA. Images are prettier at low function; renograms for obstruction, transplant perfusion/function, and differential uptake are common. Still used with diuretic or ACE-inhibitor protocols when ordered.
QC trap: radiochemical purity and light-sensitive kit handling per package insert; free Tc or impurities alter background.
DMSA — Cortex
Tc-99m DMSA binds to renal cortex . Image 2–4 hours after injection for scars and relative cortical function— not a first-line dynamic obstruction agent. SPECT may help. Pediatric GU infection workups are classic use cases.
Do not confuse: DMSA = morphology/scars; MAG3/DTPA = dynamic function/excretion.
Shared Renal Prep and Pitfalls
Hydration and empty bladder (catheter if needed) for accurate drainage curves.
Time diuretic relative to protocol (F+0, F+20, etc.).
Hold ACE inhibitors or give captopril only as protocol dictates—wrong med timing invalidates captopril studies.
Infiltrated dose destroys quantitative renography.
Know left vs right differential function pitfalls (ROI drawing, background subtraction, overlying activity).
GU-Related Notes
Bladder activity on bone scans is expected; residual urine can hide pelvic lesions—post-void images help. Vesicoureteral reflux can be studied with radionuclide cystography (often Tc-99m sulfur colloid or DTPA per lab)—know that reflux studies are a different protocol family from DMSA cortical scans.
Comparison Snapshot
- Task Best Tc-99m choice among this group
- Whole-body osteoblastic mets MDP or HDP
- Three-phase osteomyelitis MDP/HDP
- GFR-oriented renogram DTPA
- Renogram when function is poor MAG3
- Cortical scar mapping DMSA
For Domain III items, first ask “filtration, secretion, cortical binding, or bone mineral?” —the agent almost chooses itself once physiology is clear.